Featuring market attractiveness scoring, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, deeper supply chain intelligence, emerging startup tracking, and granular product-level insights, The Business Research Company’s 2026 market reports are built to deliver research that is both more actionable and more strategically valuable.
Biologics Manufacturing Market CAGR Outlook And Future Development
The biologics manufacturing market has experienced substantial expansion in recent years. Its size is projected to increase from $42.04 billion in 2025 to $50.69 billion in 2026, growing at a compound annual growth rate (CAGR) of 20.6%. Historically, this market expansion can be attributed to the proliferation of recombinant protein therapeutics, the early embrace of mammalian cell culture systems, a rise in vaccine manufacturing capacity, the growing trend of outsourcing biologics production, and improvements in purification technologies.
The biologics manufacturing market is anticipated to experience significant expansion in the coming years. It is projected to achieve a valuation of $106.08 billion by 2030, growing at a compound annual growth rate (CAGR) of 20.3%. This surge in the forecast period can be primarily attributed to the escalating demand for personalized biologics, increased investments in adaptable manufacturing platforms, the broadening of biosimilar development, the wider integration of digital bioprocessing tools, and a concentrated effort on cost-effective, large-scale production. Furthermore, prominent trends throughout this forecast timeframe encompass the increasing adoption of single-use bioprocessing systems, the rising deployment of continuous biomanufacturing, a growing need for high-volume monoclonal antibody production, the expansion of modular biologics facilities, and enhanced integration of advanced process control.
Get A Free Sample Report With In-Depth Market Insights:
Biologics Manufacturing Market Growth Factors Behind Sustained Expansion
An increasing incidence of chronic illnesses is anticipated to fuel the expansion of the biologics manufacturing market in the future. These are enduring health conditions that manifest gradually and persist over long durations, frequently necessitating ongoing medical attention. The increased occurrence of chronic diseases is partly attributable to sedentary habits, since extended periods of sitting and insufficient physical exercise elevate the likelihood of developing ailments like heart conditions and diabetes. Biologics manufacturing improves the management of chronic diseases by creating specific therapies, which are effective for ailments including diabetes, cancer, and autoimmune disorders. This process lessens the impact of diseases through the supply of reliable, premium biologic drugs, thereby enhancing patient results and the effectiveness of treatment. As an example, in June 2024, data from the National Health Service, a government department based in the UK, revealed that 3,615,330 individuals registered with a general practitioner (GP) received a diagnosis of non-diabetic hyperglycemia or pre-diabetes (a state where blood sugar levels are elevated but not yet at diabetic levels) in 2023. This represented an 18% rise from the 3,065,825 cases reported in 2022. Consequently, the increasing incidence of chronic diseases is fueling the expansion of the biologics manufacturing market.
Biologics Manufacturing Market Segment Analysis: What Are The Core Market Categories?
The biologics manufacturing market covered in this report is segmented –
1) By Mode of Manufacturing: Contract Manufacturing, In-House Manufacturing
2) By Modality: Monoclonal Antibodies (mAbs), Biosimilar And Recombinant Proteins, Vaccines (recombinant/mRNA/Viral), Cell And Gene Therapies, Ribonucleic Acid-Based Therapeutics
3) By Disease Indication: Oncology, Autoimmune Disorders, Infectious Diseases, Neurological Disorders, Other Disease Indications
Subsegments:
1) By Contract Manufacturing: Mammalian Cell-Based Production, Microbial Fermentation Production, Cell-Free Protein Synthesis, Hybrid Manufacturing Systems
2) By In-House Manufacturing: Mammalian Cell Culture Production, Microbial Expression Systems, Continuous Bioprocessing, Single-Use Technology Production
Biologics Manufacturing Market Industry Trends Fueling Future Revenue Growth
Leading entities within the biologics manufacturing sector are prioritizing the creation of sophisticated tools, specifically integrated biologics contract development and manufacturing organization (CDMO) platforms. These initiatives aim to boost comprehensive biologics development, optimize production efficiency, and streamline supply chain integration across various therapeutic categories. An integrated biologics CDMO platform is defined as an extensive framework that unifies biologics development, manufacturing, and supply services into one cohesive system. Illustrating this trend, Catalent Inc., a US-based contract development and manufacturing enterprise, enhanced its OneBio Suite in June 2023. This expansion was designed to facilitate integrated development, production, and supply across different biologic modalities. The upgraded OneBio Suite now provides a fully integrated biologics CDMO platform, supporting a range of products including antibodies, cell and gene therapies, and mRNA-based therapeutics. It delivers complete services, spanning from initial development to fill-finish and packaging, all managed under a single contract with streamlined project oversight. This approach helps achieve quicker development cycles, greater scalability, and seamless integration of global supply networks.
Biologics Manufacturing Market Top Companies Driving Competitive Growth
Major companies operating in the biologics manufacturing market are Johnson & Johnson, F. Hoffmann La-Roche Ltd., Pfizer Inc, AbbVie Inc., Eli Lilly and Company, Novartis AG, Bristol-Myers Squibb Company, Thermo Fisher Scientific Inc., LG Life Sciences Ltd., Novo Nordisk A/S, Amgen Inc., FUJIFILM Holdings Corporation, Boehringer Ingelheim International GmbH, Teva Pharmaceutical Industries Ltd., Lonza Group Ltd., Intas Pharmaceuticals Ltd., Samsung Biologics Co. Ltd., Fareva SA, Celltrion Inc., Evotec SE
View The Full Biologics Manufacturing Market Report:
Biologics Manufacturing Market Regional Analysis And Top Geography
North America was the largest region in the biologics manufacturing market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the biologics manufacturing market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
